Alliance Medical’s acquisition of IBA Molecular has today been referred to the Competition Commission by the Office of Fair Trading (OFT).Alliance acquired the company in September 2013 in a move to secure the future UK production of the vital pharmaceutical that allows PET/CT scanning – Fluorodeoxyglucose 18F (FDG-18). The deal was supported by investors and…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2025 All rights reserved LaingBuisson 
